Arthritis

Global Psoriatic Arthritis Drug Landscape Research Report 2024: Comprehensive Insights About 20+ Companies and 25+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 6, 2024

This report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Psoriatic Arthritis pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Psoriatic Arthritis pipeline landscape.
  • A detailed picture of the Psoriatic Arthritis pipeline landscape is provided which includes the disease overview and Psoriatic Arthritis treatment guidelines.
  • The assessment part of the report embraces, in depth Psoriatic Arthritis commercial assessment and clinical assessment of the pipeline products under development.
  • Psoriatic Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

PK MED Announces FDA Clearance to Initiate Its Clinical Program for PKM-01, for Local Treatment of Gout Flares, Directly by a Phase 2 Trial

Retrieved on: 
Monday, February 26, 2024

During a Type B pre-IND meeting1, the Food and Drug Administration gave its clearance to directly initiate the clinical program for PKM-01 with a phase 2 trial for gout patients, without undertaking phase 1 studies.

Key Points: 
  • During a Type B pre-IND meeting1, the Food and Drug Administration gave its clearance to directly initiate the clinical program for PKM-01 with a phase 2 trial for gout patients, without undertaking phase 1 studies.
  • PKM-01 is a local intra-articular injection treatment for gout flares, developed by PK MED, aiming to provide a fast an effective pain relief and powerful and safe anti-inflammatory effect.
  • Thanks to its low-risk toxicity profile, PKM-01's clinical program will start directly in phase 2, which should considerably speed up time-to-market.
  • PK MED is now entering the fund-raising phase to finance PKM-01 phase 2 clinical trials.

Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary

Retrieved on: 
Tuesday, February 20, 2024

Organon (NYSE: OGN), a global healthcare company with a dedicated commitment to biosimilars, announced that the US Department of Veterans Affairs (VA) has exclusively selected HADLIMA in replacement of HUMIRA (adalimumab) for the VA National Formulary.

Key Points: 
  • Organon (NYSE: OGN), a global healthcare company with a dedicated commitment to biosimilars, announced that the US Department of Veterans Affairs (VA) has exclusively selected HADLIMA in replacement of HUMIRA (adalimumab) for the VA National Formulary.
  • "America’s veterans deserve access to quality medicines at a lower cost.
  • “We applaud the VA for its leadership in championing biosimilars and including all three of Organon’s biosimilars available in the US on its formulary."
  • HADLIMA was launched in the US to offer patients a more affordable option without compromising on safety and efficacy.

OrthoVentions Invests in Motio[OV] to Develop 3D Printed Implant and Instruments to Treat Joint Arthritis of the Big Toe

Retrieved on: 
Friday, March 8, 2024

MotioOV is developing a novel 3D printed implant and custom instruments to address stiffness and pain associated with arthritis of the first metatarsophalangeal (MTP) joint.

Key Points: 
  • MotioOV is developing a novel 3D printed implant and custom instruments to address stiffness and pain associated with arthritis of the first metatarsophalangeal (MTP) joint.
  • The solution under development will consist of various implant sizes and single-use instruments customized to complete total joint arthroplasty.
  • Complaints of arthritic toe pain account for 20-30 percent of all patient visits to foot and ankle surgeon's practice.
  • Arthritis of the MTP joint is a growing clinical burden driven by the aging population with no viable motion preserving option."

Arthritis Research Canada Celebrates 25 Years of Vital Arthritis Research

Retrieved on: 
Thursday, March 7, 2024

VANCOUVER, BC, March 7, 2024 /CNW/ - Arthritis Research Canada, a North American leader in clinical arthritis research, is proud to celebrate 25 years of advancing life-changing arthritis research with you.

Key Points: 
  • VANCOUVER, BC, March 7, 2024 /CNW/ - Arthritis Research Canada, a North American leader in clinical arthritis research, is proud to celebrate 25 years of advancing life-changing arthritis research with you.
  • Founded in 1999 to recognize the extraordinary potential that research can bring to arthritis treatment, Arthritis Research Canada has been advancing research aimed at preventing arthritis, facilitating early diagnosis, finding new and better treatments and improving the quality of life for people with arthritis.
  • "I have been with Arthritis Research Canada since its beginning, and over the past quarter century, we have made a significant difference in the lives of millions living with arthritis," said Dr. Diane Lacaille , Arthritis Research Canada's Scientific Director.
  • Throughout this year, Arthritis Research Canada will be highlighting major milestones, introducing the next generation of scientists, sharing stories of lives touched, and announcing new, innovative research to help people with arthritis thrive.

Chill. Stick. Go.: Compass Health Brands Delivers PAINCAKES® The Cold Pack That Sticks!® Bringing Disruption to The Cold Therapy Market

Retrieved on: 
Wednesday, February 28, 2024

QUINCY, Mass., Feb. 28, 2024 /PRNewswire-PRWeb/ -- Versatile and portable, PAINCAKES® is a cold pack that sticks and provides relief to sore muscles, aches, and pains.

Key Points: 
  • Versatile and portable, PAINCAKES® is a cold pack that sticks and provides relief to sore muscles, aches, and pains.
  • Each gel cold pack features a proprietary stick-and-stay technology that's been tested and proven to stick up to 100 times.
  • "We are very excited to introduce PAINCAKES® to consumers," says Tony West, Compass Health Brands' SVP of Retail.
  • This is the latest offering from Compass Health Brands, the same company that owns over 20 brands with thousands of products.

HSS Orthopedics with Stamford Health Establishes Premier Spine Center in Connecticut

Retrieved on: 
Monday, February 26, 2024

STAMFORD, Conn., Feb. 26, 2024 /PRNewswire/ -- Back pain is a complex, widespread issue across the United States, with the Centers for Disease Control and Prevention estimating that 65 million Americans are affected. Common reasons include arthritis, disc and nerve injury, muscle strain, and other underlying health conditions such as osteoporosis and scoliosis. Responding to the urgent need for increased access to high quality spine care in Connecticut, a specialist center was created last year as an extension of the collaboration between Hospital for Special Surgery (HSS) and Stamford Health.

Key Points: 
  • Responding to the urgent need for increased access to high quality spine care in Connecticut, a specialist center was created last year as an extension of the collaboration between Hospital for Special Surgery (HSS) and Stamford Health.
  • The HSS Spine Center with Stamford Health led by co-medical directors Steven J. McAnany, MD , spine surgeon at HSS, and Andrea F. Douglas, MD, FAANS, FACS , chief of Neurosurgery at Stamford Health, builds on a successful collaboration started in 2016.
  • "The HSS Spine Center with Stamford Health harnesses the expertise of our respective institutions to bring world-class patient care to the communities we serve," said Kathleen Silard, president and CEO at Stamford Health.
  • "Over the past year, hundreds of patients with back and neck conditions have benefitted from the exceptional capabilities and proven expertise we offer through the HSS Spine Center with Stamford Health."

The American Kennel Club and AKC Canine Health Foundation Launch a Canine Sports Medicine & Rehabilitation Residency Program

Retrieved on: 
Tuesday, February 20, 2024

RALEIGH, N.C., Feb. 20, 2024 /PRNewswire/ -- The AKC Canine Health Foundation (CHF), in collaboration with the American Kennel Club (AKC), announces the launch of the AKC/AKC CHF Canine Sports Medicine & Rehabilitation Residency Program.

Key Points: 
  • RALEIGH, N.C., Feb. 20, 2024 /PRNewswire/ -- The AKC Canine Health Foundation (CHF), in collaboration with the American Kennel Club (AKC), announces the launch of the AKC/AKC CHF Canine Sports Medicine & Rehabilitation Residency Program.
  • Cutting-edge medicine and health research will benefit canine athletes such as AKC conformation and performance sport participants, detection dogs, military working dogs, police dogs, and more.
  • "In supporting a Canine Sports Medicine & Rehabilitation Residency, the Foundation demonstrates its continued commitment to advancing veterinary medicine and ensuring that every dog receives the specialized care they deserve based on their unique circumstances."
  • The AKC/AKC CHF Canine Sports Medicine & Rehabilitation Residency Program builds on the success of a similar collaboration supporting specialty training in reproductive medicine and clinical genetics.

Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan

Retrieved on: 
Friday, February 16, 2024

TOKYO, Feb 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional formulation of Metoject Subcutaneous Injection for the anti-rheumatic agent, pen-type autoinjector "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate).

Key Points: 
  • TOKYO, Feb 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional formulation of Metoject Subcutaneous Injection for the anti-rheumatic agent, pen-type autoinjector "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate).
  • Based on the license agreement signed by Eisai and medac GmbH in May 2019, nippon medac will hold the marketing authorization of Metoject, while Eisai will be responsible for product distribution of Metoject in Japan.
  • This formulation incorporates the previously MHLW-approved Metoject Subcutaneous Injection pre-filled syringe formulation in a pen-type autoinjector and was developed to reduce the burden on patients and improve safety during self-injection.
  • The drug can be self-injected in two steps (1- removing the cap, 2- pressing the pen against the skin).

InventHelp Inventor Develops Specially Formulated Health Supplement (DAL-366)

Retrieved on: 
Thursday, February 15, 2024

I thought there could be an all-natural and easy-to-consume supplement to help with various ailments," said an inventor, from Fort Worth, Texas, "so I invented the PINEAPPLE.

Key Points: 
  • I thought there could be an all-natural and easy-to-consume supplement to help with various ailments," said an inventor, from Fort Worth, Texas, "so I invented the PINEAPPLE.
  • My nutritious formula could increase energy, boost the immune system, and help relieve the symptoms of arthritis, COVID-19 and its variants, inflammation, etc."
  • The invention provides an all-natural supplement to help heal the body of various ailments, bad bacteria, mucus, etc.
  • As a result, it may help boost the immune system and it could provide added health benefits.